MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Virology_Antiviral, Antivirus
AlloVir, Inc. (NASDAQ:ALVR)*
Organization & Developments: AlloVir
Parents
AlloVir, Inc. (NASDAQ:ALVR)*
Children
*Proprietary platform develops allogeneic, off-the-shelf VSTs (Virus-Specific T Cells) designed to restore immunity in patients with T cell deficiencies.
2019: Biotech builder ElevateBio reveals its first portfolio company: AlloVir
2021: AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients
2022: AlloVir: Solid Data, But Market Isn't Paying Attention_ seekingalpha.com
2022: Granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses
2023: An Intriguing $3 Biotech Concern (NASDAQ:ALVR)
2024: Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce
2024: Struggling AlloVir finds new identity by merging into eye disease biotech
Jumps
Finance & Acquisitions: AlloVir
Key People: AlloVir